Tamarixetin for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 25 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Tamarixetin may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed tamarixetin in detail.

Studies suggesting benefit with tamarixetin

Singh et al., Flavonoids as Potent Inhibitor of SARS-CoV-2 Nsp13 Helicase: Grid Based Docking Approach, Middle East Research Journal of Pharmaceutical Sciences, doi:10.36348/merjps.2023.v03i04.001

The corona virus (COVID-19) is an enveloped RNA virus with diverse origins in both people and wildlife. It has been determined that six separate species are the cause of human disease. Viral infections have a significant impact on human disease, and one of the most recent worldwide epidemics is the emergence of the new corona. The SS-RNA virus from the enveloped corona virus family is what caused the potentially lethal SARS (Severe Acute Respiratory Syndrome) virus. In many countries throughout the world, sickness is spreading quickly. As of March 26, 2020, there has been 462,684 confirmed cases and 20,834 fatalities documented abroad. COVID-19 was deemed a pandemic by the World Health Organisation (WHO) on March 11, 2020. Numerous drug studies are now underway, and some of the results are positive. The only way to combat the virus, however, is through preventative measures as there is no vaccination. The goal of the current study was to use a molecular docking approach to evaluate flavonoids's potential against SAR-CoV-2 infection. Elucidation of the proposed mechanism of action of natural flavonoid (Quercetin, Isorhametin, Rutin and Tamaraxiten) against SAR-CoV-2 infection.

Bogoyavlenskiy et al., Computer Analysis of the Inhibition of ACE2 by Flavonoids and Identification of Their Potential Antiviral Pharmacophore Site, Molecules, doi:10.3390/molecules28093766

In the present study, we investigated the antiviral activities of 17 flavonoids as natural products. These derivatives were evaluated for their in vitro antiviral activities against HIV and SARS-CoV-2. Their antiviral activity was evaluated for the first time based on POM (Petra/Osiris/Molispiration) theory and docking analysis. POM calculation was used to analyze the atomic charge and geometric characteristics. The side effects, drug similarities, and drug scores were also assumed for the stable structure of each compound. These results correlated with the experimental values. The bioinformatics POM analyses of the relative antiviral activities of these derivatives are reported for the first time.